|The photo (courtesy of Merck & Co., Inc.) shows how the growth of bacteria on the agar in a culture dish has been inhibited by the three circular colonies of the fungus Penicillium notatum. The antibiotic penicillin, diffusing outward from the colonies, is responsible for this effect. Today, penicillin is made from cultures of Penicillium chrysogenum that has been specially adapted for high yields.
These synthetic molecules block the final step in the conversion of PABA to folic acid so they, too, block nucleotide and protein synthesis in bacteria but not in mammals.
Trimethoprim is one of several in current use. These folic acid analogs are often used in combination with a sulfa drug.
The beta-lactams get their name from the characteristic ring structure — shown here in blue — that they all share. (The green arrow shows the bond that is broken by the beta-lactamases that are synthesized by many penicillin-resistant bacteria.)They include the
This elaborate, covalently cross-linked structure provides the great strength of the cell wall. It also leads to the remarkable conclusion that the bacterial cell wall meets the definition of a single molecule!
The beta-lactam antibiotics bind to and inhibit enzymes needed for the synthesis of the peptidoglycan wall. While they have little effect on resting bacteria, they are lethal to dividing bacteria as defective walls cannot protect the organism form bursting in hypotonic surroundings.
|Link to discussion of translation.
|Link to a discussion of the prokaryotic nature of gene expression in mitochondria.
These antibiotics bind to the large (50S) subunit of the bacterial ribosome where they block the growing peptide chain from exiting the ribosome thus severely hindering protein synthesis. Because of their similar action, the development of antibiotic resistance to one usually extends to all the others.
Macrolides are also products of actinomycetes (soil bacteria) or semi-synthetic derivatives of them.
Erythromycin, azithromycin (Zithromax®), and clarithromycin (Biaxin®) are a commonly-prescribed macrolides.
The first member of this group was also isolated from a soil actinomycete (found near Lincoln, Nebraska). A semi-synthetic derivative, called clindamycin (Cleocin®), is now widely used against Gram-positive bacteria.
Quinupristin and dalfopristin are examples. As of 1 October 1999, they will be sold as a mixture under the trade name Synercid. Combined, they show great promise in treating certain infections resistant to vancomycin — currently the antibiotic of last resort for some hospital-acquired infections.
Ketolides are derivatives of macrolides. Telithromycin (Ketek®) is an example.
Ketolides also bind to the 50S subunit of the bacterial ribosome. In so doing they cause it to induce frameshifts during translation. Bacteria that have become resistant to macrolides, lincosamides, and streptogramins are still susceptible to ketolides.
Ciprofloxacin (Cipro®), levofloxacin and norfloxacin are examples. Cipro is the preferred antibiotic for people who have been intentionally exposed to anthrax, although some other antibiotics appear to be equally effective.
The topoisomerases in eukaryotes are not affected.
This new antibiotic blocks DNA replication by inhibiting both a bacterial topoisomerase and the bacterial gyrase. The gyrase is an essential part of the complex that unwinds DNA.
FDA approval is expected in 2023.
It behaves as a detergent, increasing the permeability of the membranes that encase Gram-negative bacteria and causing the contents of the bacterial cell to leak out.
This semi-synthetic antibiotic binds to the bacterial RNA polymerase and prevents it from carrying out its role in transcription. Its affinity for the equivalent eukaryotic enzyme is much lower. Rifampin is also known as rifampicin.
This antibiotic blocks the action of the bacterial isoleucine tRNA synthetase, the enzyme responsible for attaching the amino acid isoleucine (Ile) to its tRNA in preparation for protein synthesis, so protein synthesis is inhibited. It spares the equivalent eukaryotic enzyme.
Cycloserine inhibits synthesis of the bacterial cell wall but by a different mechanism than the beta-lactam antibiotics discussed above. Cycloserine is an analog of D-alanine and blocks the incorporation of D-alanine into the peptide bridges in the bacterial cell wall (look back). It is derived from an actinomycete.
These products of another actinomycete achieve their effect by interfering with the 30S subunit of the bacterial ribosome. Spectinomycin (trade name = Trobicin®) is an example. It is particularly effective against the gonococcus, the bacterium that causes the sexually-transmitted disease (STD) gonorrhea.
Glycopeptides also interfere with the synthesis of the bacterial cell wall but by a different mechanism than the beta-lactams.
Vancomycin is a widely-used glycopeptide in the U.S. It binds to the D-alanines on the precursors of the peptidoglycan cross bridges preventing their cross-linking (look back). It has become the antibiotic of last resort as resistance to the other antibiotics has become more and more common.
The first of these new antibiotics, linezolid (Zyvox®), was approved by the U.S. Food and Drug Administration on 19 April 2000. It is effective against many Gram-positive bacteria that have developed resistance to the older antibiotics.
Linezolid attacks a previously-unexploited chink in the bacterium's armor: the proper assembly of the two ribosomal subunits (30S and 50S). It does not affect eukaryotic ribosomes — and thus translation of mRNAs in the cytosol. However, it does affect the bacterial-like mitochondrial ribosomes and can interfere with the synthesis of those mitochondrial proteins synthesized by them.
These are natural compounds derived from a species of Streptomyces. The one now in clinical use is daptomycin (Cubicin®). It is effective against Gram-positive bacteria. It attacks another previously-unexploited chink in the bacterial armor — the integrity of its cell membranes.
So far there is no evidence of bacteria developing resistance against it.
None of the antibiotics discussed above is effective against all bacterial pathogens.
Example: In the U.S. in the decade from 1985–1995, resistance of Shigella (which causes gastrointestinal illness) to ampicillin grew from 32% to 67%. And, while only 7% of these isolates were resistant to the combination of sulfamethoxazole and trimethoprim at the start of the decade, that figure had grown to 35% by the end of the decade.Bacteria develop resistance by acquiring genes encoding proteins that protect them from the effects of the antibiotic. In some cases the genes arise by mutation; in others, they are acquired from other bacteria that are already resistant to the antibiotic. The genes are often found on plasmids which spread easily from one bacterium to another — even from one species of bacterium to another.
An alarming number of human pathogens have acquired genes to combat all the presently-used antibiotics except vancomycin and recently vancomycin-resistant bacteria have appeared. These multidrug-resistant strains are particularly common in hospitals where antibiotic use is heavy, and the patients often have weakened immune systems.
|How transposons contribute to multidrug resistance.
Farmers can help as well by avoiding the use of antibiotics in their livestock that are similar to those used in humans. Antibiotics are widely used in healthy livestock to improve their growth rate (by an unknown mechanism).
An article in the 20 May 1999 issue of The New England Journal of Medicine documents the recent development of quinolone resistance in Campylobacter jejuni, the most frequent bacterial cause of gastroenteritis in humans. The rise coincides with the approval in 1995 of the use of quinolones by U. S. poultry farmers (chickens also become infected by C. jejuni).
Similar recent increases in fluoroquinolone-resistant C. jejuni have been reported in the Netherlands and also in Spain (where as many as 50% of human infections are now caused by bacteria resistant to the antibiotic). In each country, the appearance of resistant strains followed the widespread introduction of quinolone treatment for animals.
Drug companies — after many years of complacency — are now responding to the threat of antibiotic-resistant bacteria. Over a dozen new antibiotics are being developed and some have already reached clinical trials.Many of these are semi-synthetic modifications of already-existing antibiotics, including new
Others are entirely new, attacking previously-unexploited chinks in the bacterial armor.